MonTa Biosciences is a start-up biotech company located in the largest university park in Denmark and is working on the development of a novel Cancer Immunotherapy technology.
MonTa Biosciencess Monocytes Targeting technology has been developed in collaboration between Bioneer A/S and DTUNanotech.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]
MonTa Biosciencess is developing proprietary technology for targeting monocytes and delivery of a toll-like receptor (TLR) agonist in fresh blood using liposomes with a positively charged surface chemistry.
In 2014, MonTa Biosciences was awarded a _Proof-of-Concept grant from Copenhagen Spin-puts to support the early development of the company. It also received a Pre-Seed Grant from Novo Seeds.
Recover your password.
A password will be e-mailed to you.